journal
MENU ▼
Read by QxMD icon Read
search

Innovations in Clinical Neuroscience

journal
https://www.readbyqxmd.com/read/28584697/managing-your-aging-patient-population
#1
Ann L McNary
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584696/redefining-acute-relapses-in-multiple-sclerosis-implications-for-phase-3-clinical-trials-and-treatment-algorithms
#2
EDITORIAL
Jagannadha Avasarala
Relapses in multiple sclerosis are defined as periods of clinical worsening and radiological progression. Magnetic resonance imaging data, however, are not always supportive of "clinical worsening," and clinical symptoms of worsening may not always be present in cases of acute relapse. In the pharmaceutical domain, this discordance between "clinical worsening" and "radiological progression" has never been fully elucidated, and no Phase 3 clinical study has addressed this conundrum. Thus, the true number of acute relapse cases enrolled in Phase 3 clinical studies remains unclear...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584695/neuroendocrine-autonomic-and-metabolic-responses-to-an-orexin-antagonist-suvorexant-in-psychiatric-patients-with-insomnia
#3
Masaru Nakamura, Takahiko Nagamine
Aim: The aim of this study was to investigate the neuroendocrine, autonomic, and metabolic system responses to suvorexant in psychiatric subjects with insomnia. Design: This prospective study was conducted in Kusatsu Hospital in Hiroshima, Japan and included 40 psychiatric inpatients treated with suvorexant from December 2014 to April 2016. Methods: Questionnaire of Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9) scores were checked at baseline, Week 2, and Week 4, and fasting serum levels of prolactin, insulin, cortisol, noradrenaline, white blood cell count, and average pulse rate were measured at baseline and Week 4 and Week 8 after suvorexant initiation...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584694/liothyronine-for-depression-a-review-and-guidance-for-safety-monitoring
#4
REVIEW
Katie T B Touma, Allysa M Zoucha, Jonathan R Scarff
Objective: The objective of this review is to discuss triiodothyronine's (T3, liothyronine) mechanism of action, efficacy in enhancement and augmentation trials, and dosing and safety considerations for the treatment of depression. Method: A literature search of PubMed was performed using search terms depression, augmentation, antidepressant, and liothyronine. Only English-language studies of subjects with unipolar depression were included from the past 50 years. Results: Most studies have shown that liothyronine is an efficacious enhancement and augmentation strategy for depression in combination with antidepressants, primarily tricyclic antidepressants and selective serotonin reuptake inhibitors...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584693/interactive-voice-response-and-text-based-self-report-versions-of-the-electronic-columbia-suicide-severity-rating-scale-are-equivalent
#5
Chad Gwaltney, James C Mundt, John H Greist, Jean Paty, Brian Tiplady
Objectives: Our study objective was to compare the equivalence of a new version of the electronic Columbia-Suicide Severity Rating Scale that was administered on a tablet device with the existing interactive voice response version in order to support the prospective monitoring of suicidal ideation and behavior in clinical trials and clinical practice. Design: This was a randomized, crossover-equivalence study with no treatment intervention. Setting: The study setting was a psychiatric hospital. Participants: Fifty-eight recently admitted psychiatric inpatients and 28 employees of the hospital site were included in the study...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584692/human-embryonic-stem-cells-in-the-treatment-of-autism-a-case-series
#6
Geeta Shroff
Background: Autism spectrum disorder is a neurodevelopmental disorder accompanied by weak immune system and neuroinflammation. Multiple factors contribute to etiology of autism spectrum disorder including genetic disorders, environmental substances/toxins, imbalanced immune system, encephalitis, and viral infections. Autism spectrum disorder is an incurable disease; however, it can be managed by educational and medical interventions. Human embryonic stem cell therapy has been shown to improve blood perfusion in the brain; thus, this therapy may be effective in improving motor skills, social skills, and cognition in patients with autism spectrum disorder...
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28584691/modafinil-augmentation-therapy-in-patient-with-traumatic-brain-injury
#7
Oleg V Tcheremissine, James C Rachal
No abstract text is available yet for this article.
March 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28409061/severe-hypoglycemia-associated-with-tiapride-in-an-elderly-patient-with-diabetes-and-psychosis
#8
Takahiko Nagamine
No abstract text is available yet for this article.
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386523/risk-management-issues-when-taking-locum-tenens-assignments
#9
Charles D Cash
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386522/ketamine-therapy-for-treatment-resistant-depression-in-a-patient-with-multiple-sclerosis-a-case-report
#10
Michael M Messer, Irina V Haller
Objective: Depression is a common condition among patients with multiple sclerosis and often becomes resistant to oral antidepressants. We report a patient with multiple sclerosis who developed severe treatment-resistant depression and who was successfully treated with intravenous ketamine over the period of two years. Methods: Ketamine treatment protocol included an initial series of six treatments administered every other day, followed by a maintenance schedule. Ketamine was administered intravenously at 0...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386521/micrornas-as-biomarkers-for-psychiatric-conditions-a-review-of-current-research
#11
REVIEW
Anoop Narahari, Mariyah Hussain, Venkatesh Sreeram
Neural-derived exosomes can be used as diagnostic markers to screen for various psychiatric conditions. These intravenously injected exosomes carry the potential to cross the blood brain barrier and deliver miRNA molecules specifically to neurons, microglia, and oligodendrocytes in the brain, resulting in specific gene knockdown. Here the authors review and discuss the current research on microRNA molecules and the therapeutic roles they may potentially play in treating depression, bipolar disorder, and schizophrenia...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386520/behavioral-and-stereological-analysis-of-the-effects-of-intermittent-feeding-diet-on-the-orally-administrated-mdma-ecstasy-in-mice
#12
Zeinab Ebrahimian, Zeinab Karimi, Mohammad Javad Khoshnoud, Mohammad Reza Namavar, Bahram Daraei, Mohsen Raza Haidari
Background: 3,4-methylenedioxy-methamphetamine or MDMA (also known as "ecstasy" or "molly") is a commonly abused drug that affects behavior and can lead to neuronal damage. Intermittent feeding is an effective dietary protocol that promotes neuroprotection and improves behavioral outcomes in animal models of neurotoxicity and neurodegenerative diseases. In this study, we investigated the behavioral and histological outcomes of the effect of intermittent feeding on the orally administered MDMA in mice. Methods: The animals (male albino mice) were divided into four groups: ad libitum (AL), intermittent feeding (IF) (food given every other day), and AL and IF control groups...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386519/performance-based-and-observational-assessments-in-clinical-trials-across-the-alzheimer-s-disease-spectrum
#13
REVIEW
Philip D Harvey, Stephanie Cosentino, Rosie Curiel, Terry E Goldberg, Jeffrey Kaye, David Loewenstein, Daniel Marson, David Salmon, Keith Wesnes, Holly Posner
Assessment of the earlier stages of Alzheimer's disease requires different strategies than those previously developed for fully syndromal Alzheimer's disease . This challenge is further magnified in very early stages, where symptomatology may be minimal and functional deficits very subtle to absent. This paper reviews strategies for performance-based assessment of the early stages of Alzheimer's disease, including assessments of cognition, functional capacity, and social cognition. Meetings with an International Society for CNS Clinical Trials and Methodology working group served as the basis for this paper and its companion...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386518/outcomes-assessment-in-clinical-trials-of-alzheimer-s-disease-and-its-precursors-readying-for-short-term-and-long-term-clinical-trial-needs
#14
Holly Posner, Rosie Curiel, Chris Edgar, Suzanne Hendrix, Enchi Liu, David A Loewenstein, Glenn Morrison, Leslie Shinobu, Keith Wesnes, Philip D Harvey
An evolving paradigm shift in the diagnostic conceptualization of Alzheimer's disease is reflected in its recently updated diagnostic criteria from the National Institute on Aging-Alzheimer's Association and the International Working Group. Additionally, it is reflected in the increased focus in this field on conducting prevention trials in addition to improving cognition and function in people with dementia. These developments are making key contributions towards defining new regulatory thinking around Alzheimer's disease treatment earlier in the disease continuum...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386517/virtual-reality-and-medical-inpatients-a-systematic-review-of-randomized-controlled-trials
#15
REVIEW
Julieta Dascal, Mark Reid, Waguih William IsHak, Brennan Spiegel, Jennifer Recacho, Bradley Rosen, Itai Danovitch
Objective: We evaluated the evidence supporting the use of virtual reality among patients in acute inpatient medical settings. Method: We conducted a systematic review of randomized controlled trials conducted that examined virtual reality applications in inpatient medical settings between 2005 and 2015. We used PsycINFO, PubMed, and Medline databases to identify studies using the keywords virtual reality, VR therapy, treatment, and inpatient.Results: We identified 2,024 citations, among which 11 met criteria for inclusion...
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28386516/discussing-sexual-health-after-traumatic-brain-injury-an-unmet-need
#16
Rocco Salvatore CalabrĂ², Margherita Russo, Antonino Naro
No abstract text is available yet for this article.
January 2017: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210526/encephalopathy-or-psychosis
#17
Malathi Latha Perugula, Steven Lippmann
No abstract text is available yet for this article.
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210525/ransomware-minimizing-the-risks
#18
Justin Pope
This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS, Inc. (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation, education and onsite risk management audits, and other resources to healthcare providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company...
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210524/sympathetic-nerve-entrapment-point-injection-as-an-antireflux-procedure-for-refractory-laryngopharyngeal-reflux-a-first-case-report-of-innovative-autonomic-regulation
#19
Sangsoo Lee, Chang Jin Oh, Jeong Won Seong
Surgical treatment is not suitable for laryngopharyngeal reflux that is refractory to proton pump inhibitors. We present a case of proton pump inhibitor-refractory laryngopharyngeal reflux that was successfully treated with sympathetic nerve entrapment point injection. The patient had previously been diagnosed with laryngopharyngeal reflux and treated with proton pump inhibitors for six months without substantial improvement. After sympathetic nerve entrapment point injection treatment, her reflux symptom index improved from 15 points to 1 point, and this response was maintained for six months...
November 2016: Innovations in Clinical Neuroscience
https://www.readbyqxmd.com/read/28210523/complete-recovery-from-cardiac-arrest-caused-by-risperidone-induced-hypothermia
#20
Takahiko Nagamine
Hypothermia is a rare adverse effect of risperidone and is associated with ventricular arrhythmias, which may lead to intensive care unit admission and sometimes death. We describe a patient with schizophrenia who was taking risperidone and who, after falling into a hypothermic state, suffered cardiac arrest. Observations of the case and a brief literature review are provided.
November 2016: Innovations in Clinical Neuroscience
journal
journal
43359
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"